Biotechnology

JINYU

JINYU released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 346.46 M, actual EPS CNY 0.07

JINYU released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 354.01 M, actual EPS CNY -0.05

JINYU released FY2025 annual earnings on April 22 After-Market BJT, actual revenue CNY 1.396 B (forecast CNY 1.363 B), actual EPS CNY 0.09 (forecast CNY 0.165)

JINYU to Release FY2026 Q1 Earnings on April 23 After-Market BJT

JINYU to Release FY2025 Annual Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 1.363 B, EPS CNY 0.165

JINYU released FY2025 9 Months Earnings on October 27 Pre-Market (BJT), actual revenue CNY 1.042 B, actual EPS CNY 0.1358

JINYU released FY2025 Q3 earnings on October 27 Pre-Market (BJT), actual revenue CNY 422.84 M, actual EPS CNY 0.0832

JINYU FY2025 Q3 Earnings Release on October 24 Pre-Market BJT

JINYU released FY2025 Semi-Annual Earnings on August 19 After-Market (BJT), actual revenue CNY 619.57 M (forecast CNY 769.9 M), actual EPS CNY 0.06 (forecast CNY 0.07)

JINYU released FY2025 Q2 earnings on August 19 After-Market (BJT), actual revenue CNY 268 M, actual EPS CNY -0.0174

JINYU to Release FY2025 Semi-Annual Earnings on August 20 (BJT), Forecast Revenue CNY 769.9 M, EPS CNY 0.07

Bio-Inc responds to the regulatory warning letter from Inner Mongolia CSRC and submits a rectification report

Bio 股份 Subsidiary Obtains Clinical Trial Approval for Feline Infectious Peritonitis mRNA Vaccine

Bio 股份 Subsidiary Receives Clinical Trial Approval for ASF Vaccine

Open Securities Maintains Biostar's Buy Rating

Bio Stock Expected Net Profit Decline in First Half of 2025

Bio-Share Subsidiary SuYang Ubang Successfully Developed New Veterinary Drug

Bio Stock Disposes of Investment Projects to Improve Capital Utilization

Bioshare Repurchased 15.3833 million Shares

Bio-Stock States No US Export Impact from Tariffs

600201

600195

A South African Serotype 1 foot-and-mouth disease outbreak has occurred in Xinjiang and Gansu provinces in China, affecting 6,229 cattle with 219 confirmed cases. The virus has spread to pigs. Emergency approval has been granted for vaccines from Zhongnong Weitai and JINYU. Industry analysts believe this outbreak will raise biosafety requirements for the breeding sector, potentially accelerating the scale-up of beef cattle farming and the elimination of backward capacity

Wallstreetcn

CAHIC

South African Serotype 1 Foot-and-Mouth Disease Disrupts Livestock Industry Chain

603392

603566

300142

300119

688185

06185

Huachuang Securities released a research report stating that in the first three quarters of 2023, the batch issuance volume of most vaccine varieties increased year-on-year, especially with outstanding performance in pet vaccines and ruminant vaccines. Despite the pressure of internal competition in the animal husbandry industry, the prices of veterinary raw materials have stabilized and rebounded. Focus on undervalued and resilient targets. Specific data shows significant growth in pig vaccines, poultry vaccines, and pet vaccines, reflecting the positive impact of farming profitability and the launch of new products

Zhitong

Wantai Biological

PULIKE

WALVAX

RINGPU

CanSinoBIO

CANSINOBIO

Huachuang Securities: In the first three quarters, most vaccine varieties saw year-on-year growth in batch approvals, and pet vaccines continued to maintain a high growth rate

According to the Zhitong Finance APP, JINYU released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.042 billion yuan, a year-on-year increase of 7.38%. The net profit attributable to shareholders of the listed company was 161 million yuan, a year-on-year decrease of 4.85%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 115 million yuan, a year-on-year decrease of 21.65%. The basic earnings per share were 0.15 yuan

JINYU released its performance for the first three quarters, with a net profit attributable to the parent company of 161 million yuan, a decrease of 4.85%

JINYU announced that the company will hold the fourth meeting of the twelfth board of directors on October 27, 2025, to review and approve the proposal regarding the repurchase and cancellation of part of the shares under the 2023 employee stock ownership plan. Due to 5 departing holders who have not yet unlocked their equity shares, the company will repurchase and cancel 120,000 shares at a repurchase price of 6.23 yuan per share. After the completion of this repurchase and cancellation, the company's capital structure will change, but it will not have a substantial impact on the company's operating performance and financial condition

JINYU: Plans to repurchase and cancel 120,000 shares of stock

According to the announcement from JINYU, the company has been approved by the Ministry of Agriculture and Rural Affairs of the People's Republic of China to develop a new veterinary drug, the genetically engineered subunit vaccine for Clostridium perfringens type A, in collaboration with other companies through its wholly-owned subsidiary Jinyu Baoling Biological Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinyu Baoling"), in accordance with the national "Veterinary Drug Management Regulations" and "Veterinary Drug Registration Measures." The "New Veterinary Drug Registration Certificate" has been issued

JINYU: The gene-engineered subunit vaccine for bovine gas gangrene (Type A) has obtained a new veterinary drug registration certificate

HuaChuang Securities released a research report indicating that since 2025, the prices of veterinary raw materials have stabilized and rebounded, especially for macrolide products, where prices and profits have significantly improved. From January to August, the batch issuance data for vaccines saw a substantial year-on-year increase, with pet vaccines such as rabies vaccine and feline trivalent vaccine growing by 16.8% and 78.9%, respectively. The prices of veterinary raw materials rebounded since late August, with the VPI index rising by approximately 2.1%. The tightening of supply and increased demand have driven price increases, particularly benefiting products like florfenicol as market competition eases

Huachuang Securities: In August, the growth of vaccines for diarrhea, brucellosis, and feline trivalent was strong, and the raw materials for veterinary drugs are entering a peak season with price increases

JINYU released its semi-annual report for 2025, reporting an operating income of 620 million yuan during the reporting period, a year-on-year increase of 1.28%. The net profit attributable to shareholders of the listed company was 60.424 million yuan, a year-on-year decrease of 50.84%; the net profit after deducting non-recurring gains and losses was 32.1906 million yuan, a year-on-year decrease of 70.16%. The basic earnings per share were 0.06 yuan

JINYU released its performance for the first half of the year, with a net profit attributable to the parent company of 60.424 million yuan, a year-on-year decrease of 50.84%

The wholly-owned subsidiary of JINYU, Yangzhou Youbang Biopharmaceutical Co., Ltd., and Jinyu Baoling Biopharmaceutical Co., Ltd. jointly developed the inactivated vaccine for porcine parvovirus vector (rPP03 strain), which has obtained a new veterinary drug registration certificate. This move reflects the company's emphasis on research and development innovation, enriches the product line of vaccines for pigs, and enhances market competitiveness and sustainable development capabilities

JINYU's subsidiary has obtained a new veterinary drug registration certificate

688098

002688

Guohai Securities released a research report indicating that the domestic animal health industry is undergoing structural adjustments, with sales growth slowing to 3.7% from 2020 to 2023, and gross profit declining by 3.2%. As pet health awareness increases, pet medical care and overseas expansion will become new growth points. Leading companies are expected to gain larger market shares due to their rich product offerings and investment in research and development. Competition within the industry is intensifying, with frequent price wars, putting pressure on small and medium-sized enterprises

Shen Lian Biomedical

Jinhe Biotechnology

Guohai Securities: The "Matthew Effect" in the animal protection industry intensifies, and pet pharmaceuticals and overseas expansion are expected to open up medium to long-term growth space

According to the Qichacha APP, recently, Zhejiang Jinyu Baoling Supply Chain Co., Ltd. was established with a registered capital of 10 million yuan. Its business scope includes: supply chain management services; Internet of Things application services; research and development of biological feed, etc. Qichacha's equity penetration shows that the company is jointly held by JINYU's wholly-owned subsidiary Jinyu Baoling Biopharmaceutical Co., Ltd. and others

JINYU and others established a supply chain company in Zhejiang

JINYU(600201.SH)